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We assembled a collection of 73 Capnocytophaga cani-
morsus isolates obtained from blood cultures taken from 
patients treated at Helsinki University Hospital (Helsinki, 
Finland) during 2000–2017. We serotyped these isolates by 
PCR and Western blot and attempted to correlate pathogen 
serovar with patient characteristics. Our analyses showed, 
in agreement with previous research, that 3 C. canimorsus 
serovars (A–C) caused most (91.8%) human infections, de-
spite constituting only 7.6% of isolates found in dogs. The 
3 fatalities that occurred in our cohort were equally repre-
sented by these serovars. We found 2 untypeable isolates, 
which we designated serovars J and K. We did not detect 
an association between serovar and disease severity, im-
mune status, alcohol abuse, or smoking status, but dog 
bites occurred more frequently among patients infected with 
non-A–C serovars. Future research is needed to confirm 
serovar virulence and develop strategies to reduce risk for 
these infections in humans.
Capnocytophaga canimorsus is a gram-negative, rod-shaped, usually commensal bacteria of dog and 
cat oral flora that causes rare but potentially severe in-
fections in humans (1,2). Even with administration of 
adequate antimicrobial therapy, C. canimorsus–induced 
septicemia can progress to a debilitating disease or sep-
tic shock and can cause a mortality rate as high as 30%. 
Annual incidence of C. canimorsus infections has been 
estimated at 0.5–0.67 cases/1 million persons (3,4), but 
in a retrospective study, a prevalence of 4.1 cases/1 mil-
lion persons was estimated (5); this discrepancy prob-
ably resulted from the choice of diagnostics. The clinical 
manifestation of C. canimorsus infection might be mild, 
with influenza-like symptoms and intestinal complaints 
(1), a disease severity not always reaching the threshold 
for a blood culture. Moreover, C. canimorsus is a fas-
tidious and slow-growing organism, rendering its culture 
and isolation difficult (2).
Human exposure to a dog’s oral flora can occur through 
a bite or scratch or even through just being in close prox-
imity to the animal (1,5). Although splenectomy, asplenia, 
alcohol abuse, smoking, and advanced age are often de-
scribed as predisposing factors for severe illness caused by 
this bacterium, up to 40% of patients have no obvious risk 
factor (1); thus, C. canimorsus should not be considered 
exclusively an opportunistic pathogen.
C. canimorsus is enveloped by a lipooligosaccharide 
and a capsule consisting of units of the same O antigen 
but assembled by different polymerases (6). The capsule 
confers to C. canimorsus resistance to the bactericidal ef-
fects of human serum and phagocytosis by macrophages 
(6). One study showed that despite the seemingly vast rep-
ertoire of capsular serovars among C. canimorsus isolates 
from dog mouths, 3 serovars (A, B, and C) are associated 
with most human infections (7). However, this finding was 
from a study carried out with just 25 isolates from patients 
worldwide. To validate this finding, we evaluated the se-
rovars present in a collection of 73 isolates from patients 




HUSLAB (Helsinki) is a central laboratory that offers 
microbiological services to the whole Helsinki Hospi-
tal District, which encompasses the city of Helsinki and 
surrounding municipalities. The laboratory maintains a 
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frozen archive of bacterial isolates obtained from pa-
tient blood cultures. For the purposes of this study, we 
searched laboratory records for blood cultures positive 
for C. canimorsus during 2000–2017; a corresponding 
frozen bacteria isolate could be found for 78 patients. Of 
these frozen isolates, we could grow and analyze 73. To 
correlate analyses with clinical data, we searched patient 
journals, electronic patient records, and laboratory da-
tabases for patient characteristics, clinical information, 
and laboratory data. We recorded patient age, sex, con-
current medical conditions, medications administered, 
immune status, lifestyle factors, and type of contact 
with dogs (bitten, contact but not bitten, or not known), 
whenever the information was available. Of the clini-
cal data, we recorded the level of care, length of stay in 
the hospital, complications, 30-day and 1-year mortality 
rates, and registered coagulation and fibrinolysis labora-
tory variables. We analyzed partial thromboplastin time 
according to the Owren method (8).
The Administrative Department of Helsinki Hos-
pital District and Helsinki City College of Social and 
Health Care gave approval for obtaining this data from 
patient medical records. Because only data registers 
were used for acquiring data, obtaining informed con-
sent from patients was waived.
Bacterial Isolates and Growth Conditions
We cultured C. canimorsus bacterial isolates (Table 1) 
obtained from HUSLAB, which were originally obtained 
from blood samples of patients in Finland, as described 
previously (9). In brief, we incubated aerobic and an-
aerobic blood culture bottles with BacT/ALERT 3D (bio-
Mérieux, Marcy l’Etoile, France) for 6 days or until the 
cultures became positive. We used Gram staining and 
cultivated all positive samples on chocolate agar, fas-
tidious anaerobe agar, or heart infusion agar plates. For 
serotyping, we grew bacteria on heart infusion agar plates 
(BD Difco, Franklin Lakes, NJ, USA) supplemented with 
5% sheep blood (Oxoid, Basingstoke, UK) and 20 µg/mL 
gentamicin (Sigma-Aldrich, Darmstadt, Germany) for 48 
h at 37°C with 5% CO2.
C. canimorsus Identification by 16S rDNA Sequencing
We extracted genomic DNA directly from blood culture 
bottles or by boiling of a single colony (online Tech-
nical Appendix Table 1, https://wwwnc.cdc.gov/EID/
article/24/12/17-2060-Techapp1.pdf). We used 4 different 
amplification methods involving 8 different primers to se-
quence 16S rDNA from bacterial isolates (online Techni-
cal Appendix Tables 2, 3). When >1 primer was used to 
sequence a PCR product, we obtained the consensus se-
quence using Bioedit (https://bioedit.software.informer.
com), and we analyzed sequences using BLAST (https://
blast.ncbi.nlm.nih.gov/Blast.cgi).
Antisera Production and Adsorption
The production of antisera to serovars A–I has previ-
ously been described (7). We produced rabbit polyclonal 
anti-J (against isolate H12) and anti-K (against isolate 
H24) likewise (7). Immunizations were carried out at the 
Centre d’Economie Rurale (Aye, Belgium). The Centre 
d’Economie Rurale animal welfare committee approved 
our animal handling protocols and procedures. We ad-
sorbed anti-J and anti-K sera with a mixture of 25 iso-
lates from patients (Cc1–Cc25; online Technical Appen-
dix Table 4) to obtain polyclonal antibodies specifically 
recognizing J or K capsular serovars. We performed ad-
sorptions by incubating 250 µL of antiserum with 6 × 
109 paraformaldehyde-fixed bacteria on a rotating wheel 
at room temperature for >2 hours. We removed bacteria 
by successive centrifugations. We repeated the incuba-
tions and centrifugations 4 times. We performed capsular 
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Western blot typing‡ 
Serovar ABC A B C D E A B C D E F G H I 
H11, H16, H23, H37, H39, H42, H48, H52, H56, 
H60, H62, H70, H74, H75, H76, H78, H80 
+ + + – – –  + – – ND ND ND ND ND ND A 
H3, H4, H5, H6, H9, H14, H22, H25, H26, H30, H35, 
H38, H49, H50, H53, H55, H57, H58, H63, H65, 
H67, H68, H69, H71, H72, H73, H79 
+ – + – – –  – + – ND ND ND ND ND ND B 
H27 + – + – – –  + + – ND ND ND ND ND ND B 
H1, H7, H8, H10, H13, H15, H17, H18, H19, H20, 
H28, H29, H33, H34, H36, H43, H44, H45, H46, 
H47, H51, H59 
+ – – + – –  – – + ND ND ND ND ND ND C 
H41, H64 – – – – + –  – – – + ND ND ND ND ND D 
H31 – – – – – +  – – – ND + ND ND ND ND E 
H21 – – – – – –  – – – – – – – – + I 
H12, H24 – – – – – –  – – – – – – – – – NT 
*ND, not done; NT, nontypeable. 
†We performed PCR capsular typing using the oligonucleotides given in online Technical Appendix Table 2 (https://wwwnc.cdc.gov/EID/article/24/12/17-
2060-Techapp1.pdf). Results were interpreted as done previously (7): isolates positive for PCR ABC, A, and B were typed as A, isolates positive for PCR 
ABC and B were typed as B, and isolates positive for PCR ABC and C were typed as C. 
‡Western blot analyses on polysaccharidic structures were performed by using specific polyclonal rabbit antisera. 
 
C. canimorsus Serovar and Disease Severity
typing of C. canimorsus by Western blot, ELISA, and 
PCR as previously described (7).
Statistical Analysis
We expressed categorical data as counts and percentages 
and continuous data as medians and interquartile ranges. 
We compared categorical data between groups by Fisher 
exact test. We assumed continuous data were nonnormally 
distributed and analyzed data using Mann-Whitney U-test 
for 2 groups and Kruskal-Wallis nonparametric test for >3 
groups. Because of the retrospective nature of the study, 
many data points were unavailable for many cases (data 
were more complete for severely ill patients and less com-
plete for mildly ill patients), so we provided the number of 
patients included in each analysis. We considered p val-
ues <0.05 statistically significant and performed analyses 
using SPSS version 22 (https://www.ibm.com/analytics/ 
spss-statistics-software).
Results
Capsular Typing Collection of 73 Isolates from Finland
We identified the 73 isolates originating from Helsinki 
University Hospital (Table 1) as C. canimorsus through 
16S rDNA sequencing (online Technical Appendix 
Tables 1, 3). We subjected isolates to a PCR designed 
to detect capsular serovars A, B, and C (7); 67 of 73 
isolates were ABC positive (Table 1; online Technical 
Appendix Figure 1). We also typed these 67 strains us-
ing A-, B-, and C-specific PCR tests (7). To validate the 
PCR typing results, we performed Western blot analy-
ses with polysaccharide samples of the 73 isolates using 
antiserum specifically recognizing A, B, or C capsular 
serovars (online Technical Appendix Figure 2). This 
analysis confirmed the PCR typing results and interpre-
tation of all isolates tested, except H27. According to 
Western blot analyses, isolate H27 could be considered 
serovar A or B, but in agreement with the PCR results, 
we considered this isolate a B capsular serovar only. In 
short, 91.8% (67/73) of isolates tested were serovars A 
(n = 17), B (n = 28), or C (n = 22).
We then subjected isolates to PCR analyses for the 
detection of capsular types D and E, which have previ-
ously been detected among C. canimorsus isolates from 
human infections (7). Two isolates were serovar D and 1 
serovar E (online Technical Appendix Figure 1), findings 
that were confirmed by Western blot analyses (Table 1; 
online Technical Appendix Figure 2). We tested the 3 re-
maining nontypeable (non-A–E) isolates by Western blot 
for capsular types F–I, which have only been detected in 
isolates obtained from dogs (7). Isolate H21 was typed as 
serovar I, leaving only 2 strains (H12 and H24) not typed 
of the 73 tested.
We raised rabbit antisera against H12 and H24 bacte-
ria and adsorbed antisera with related bacteria strains. The 
2 new antisera recognized only the capsule of the isolate 
against which they were raised, indicating the 2 isolates be-
longed to 2 new serovars, which we named J and K (online 
Technical Appendix Figure 2). Thus, the 73 C. canimorsus 
isolates from the Helsinki University Hospital collection 
comprised 8 serovars (Figure 1, panel A); A, B, and C dom-
inated (91.8%), consistent with the findings of the previous 
study involving 25 worldwide isolates (Figure 1, panel B) 
(7). The distribution of serovars A (p = 0.071), B (p = 0.47), 
C (p = 0.20), D (p = 0.27), E (p = 0.45), and I–K (p = 1) 
was not significantly different between the 2 collections (all 
p values analyzed by Fisher exact test; Figure 1, panel C).
Screening of Dog Isolates for Capsular Serovars  
J and K
We next tested for the prevalence of the J and K capsu-
lar serovars in a previously described collection of C. 
canimorsus isolates obtained from mouths of healthy dogs 
(7,10). We screened these 52 dog isolates by ELISA using 
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Figure 1. Prevalence of capsular serovars among Capnocytophaga canimorsus isolates from patients and dogs. A) Prevalence among 
73 isolates from patients in Helsinki, Finland, 2000–2017. B) Prevalence among 25 isolates acquired from patients worldwide. C) 
Prevalence among pooled samples (n = 98). D) Prevalence among 52 isolates from dog mouths, Switzerland and Belgium. Percentages 
do not add up to 100% because of rounding. A portion of the data presented in panels B and D were previously published (7).
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the antisera we produced. Although no isolates reacted with 
the anti-K serum, isolate CcD35 from a dog in Switzerland 
reacted with the anti-J serum (Figure 1, panel D; online 
Technical Appendix Table 5). We confirmed this result 
by Western blot analysis of the polysaccharidic structures 
(online Technical Appendix Figure 2), which showed that 
capsular serovar J is thus not limited to Finland.
Correlation between Disease Severity and  
Capsular Type
We also tested the association between serovar and disease 
severity. For this investigation, the level of care was used 
as a surrogate; patients treated in a regular ward or who 
had only visited the emergency department were regarded 
as having a mild course of disease, and patients treated in 
a high-dependency or intensive care unit were regarded as 
severely ill. No statistically significant difference could be 
found in the proportions of any serovar between patients 
with mild and severe disease (p = 0.76; Figure 2, panel A). 
Among the 73 cases of C. canimorsus infection included in 
this study, 3 were fatal (Table 2). The isolates from these 
3 patients were serovars A (H80), B (H26), and C (H28). 
Extensive amputations were reported in 6 cases, among 
which included the nonsurviving patient infected with the 
capsular B isolate H26. The 5 other capsular types associ-
ated with amputations were A (n = 2, H48 and H56), B (n 
= 1, H79), and C (n = 2, H46 and H59). Therefore, capsular 
serovars A, B, and C are all capable of causing severe dis-
ease in humans.
We looked for an association between capsular serovar 
and patient immune status or lifestyle factors but found no 
statistically significant link between serovar and immune 
compromised state (p = 0.682), alcohol abuse (p = 0.982), 
or smoking (p = 0.713) (Figure 2, panels B–D). We defined 
patients as immune compromised if they had been on im-
mune suppressive medication or had recently received che-
motherapy, had a concurrent medical condition associated 
with impaired immunity or active cancer, or had undergone 
splenectomy. One of the 2 splenectomized patients had a 
severe course of disease, but both survived.
Severe C. canimorsus infections are often associated 
with purpura or petechiae, disseminated intravascular co-
agulation, and gangrene of extremities (1). In particular, 
coagulation disorders were found to be associated with 
94% of patients having C. canimorsus–induced septic 
shock in a 10-year retrospective study in Helsinki (5). In 
our study, no statistically significant association could be 
found between coagulation and fibrinolysis laboratory 
variables (platelet count, partial thromboplastin time, fi-
brin D-dimers) and capsular serovars (Table 3). Given the 
low number of cases associated with some serovars, we 
could assess only the 3 dominant serovars (A, B, and C). 
We compared coagulation and fibrinolysis disorder mark-
ers between patients with mild and severe clinical course. 
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Figure 2. Association between Capnocytophaga canimorsus capsular serovar and various patient factors, Helsinki, Finland, 2000–2017. 
A) Disease severity (n = 70); B) immune compromised (n = 73); C) alcohol abuse (n = 49); D) smoking status (n = 48); and E) contact 
with dogs (n = 73). Fisher exact test was used for statistical analysis.
C. canimorsus Serovar and Disease Severity
As expected, the analyzed variables were more affected 
in patients with a severe course of infection (Table 3). 
Of note, deviating coagulation and fibrinolysis variables 
were frequently present in patients with mild courses of 
disease, further strengthening the previously reported 
close association of C. canimorsus infection and coagula-
tion disorders.
Correlation between Type of Contact with Dog  
and Capsular Type
The type of contact with dogs did not differ among infec-
tions with any of the dominant serovars, but 4 of the 5 
patients infected with serovar D, E, I, or J had been bitten 
(Figure 2, panel E). The contact type was not known for 
the patient infected with the serovar K isolate, the fifth 
rare serotype.
Discussion
In this study, we analyzed 73 C. canimorsus isolates ob-
tained from patients treated at Helsinki University Hospi-
tal. All isolates were serotyped and found to be endowed 
with a capsular polysaccharide (CPS), further confirming 
the commonality of the presence of a CPS in C. canimor-
sus isolates (6,7). We confirmed the high prevalence of 
capsular serovars A, B, and C among isolates from human 
infections; 67 (91.8%) of 73 isolates were typed as 1 of 
these 3 serovars. No significant difference was found in the 
prevalence of these serovars between this collection of 73 
isolates from Finland and a previously studied collection of 
25 isolates obtained from cases worldwide (7). Among the 
98 C. canimorsus isolates from these 2 studies, 89 (90.8%) 
were capsular types A, B, or C. Our data confirmed that se-
rovars A, B, and C are significantly more common among 
clinical isolates than dog isolates (4/52; 7.6%), suggesting 
these serovars are more virulent than the others. Our data 
also confirmed that serovars A, B, and C are present in dif-
ferent geographic areas.
Besides the A, B, and C serovars, the Helsinki collec-
tion contained 2 other serovars: 2 isolates of serovar D and 
1 of serovar E. This observation is of high interest because 
serovars D and E were previously isolated from patients in 
the United States (n = 1), Belgium (n = 1), and Switzerland 
(n = 1) (7). Thus, although serovars D and E represent only 
4.1% and 2%, respectively, of the total clinical isolates in 
this study, these serovars should be considered virulent and 
taken into account in prophylaxis.
One patient in our cohort was infected with a se-
rovar I strain. This serovar had not been encountered 
before among humans but was found in dogs (1 in Bel-
gium and 1 in Switzerland) (7). These findings suggest 
that not only serovars A–E but also rare serovars are 
widely distributed.
Last, we describe 2 new capsular serovars, J and K, 
each with a limited (1%) prevalence in human infections. 
We tested these 2 new antisera against our collection of iso-
lates obtained from dogs in Switzerland and Belgium (10) 
and found 1 C. canimorsus isolate had a J-type CPS. Thus, 
using the 11 antisera we have that are specific to serovars 
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Table 2. Patient demographics, clinical characteristics, and 




Age, y, median (IQR) 73 55 (48.3–
64.8) 
Sex 73  
 M  38 (52.1) 
 F  35 (47.9) 
Immune compromised 73 7 (9.6) 
Smoking 48 30 (62.5) 
Alcohol abuse 49 18 (36.7) 
Contact with dog 73  
 Not known  21 (28.8) 
 Contact but not bitten  15 (20.5) 
 Bitten  37 (50.7) 
Disease severity 70  
 Regular ward or emergency 
department 
 45 (64.3) 
 High surveillance unit  11 (15.7) 
 Intensive care unit  14 (20.0) 
Length of hospital stay, d, median (IQR) 62 6 (3–13.3) 
Deaths at day 30 73 3 (4.1) 
Deaths at 1 y 61 4 (6.6) 
Amputation 73 6 (8.2) 
*Values are no. (%) patients except as indicated. IQR, interquartile range. 
†Because of missing data, number of patients in each category varied. 
 
 







Severity of illness 
p value A, n = 17 B, n = 28 C, n = 22 Severe, n = 25 Mild, n = 45 
Platelets, 109/L 150–360 109 (29–137) [2] 109 (28–140) 
[1] 
93 (23–166) [1] 0.98 23 (9.5–89) [0] 117 (95–154.3) 
[4] 
<0.001 




0.284 54 (39–66) [2] 87 (70.5–109.5) 
[31] 
<0.001 











*Values are given as median (interquartile range) [no. missing values] except as indicated. The comparison between patients with mild and severe 
courses of disease was defined by the level of care they needed. Patients with mild disease were those who were treated in a regular ward or the 
emergency department, and patients with severe disease were those treated in high surveillance or intensive care units. FiDD, fibrin D-dimers; PTT, 
partial thromboplastin time. 
†PTT was analyzed according to the Owren method (8). PTT was calculated as the ratio of the result (in seconds) from normal plasma to the result (in 
seconds) from the patient sample x 100. 
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A–K, which identified 98 human clinical isolates, we can 
only type 36.5% (19/52) of our collection of dog isolates 
from Switzerland and Belgium. This finding, again, rein-
forces the hypothesis of the existence of a large repertoire 
of CPS serovars in C. canimorsus among dog isolates.
Because C. canimorsus extensively deglycosylates hu-
man N-linked glycoproteins from cell surfaces (11–13), a 
given blood group might be a predisposing factor for C. 
canimorsus infection, but further research is needed to in-
vestigate an association between blood type and serovar. 
Blood group information was available for 55 patients 
in our cohort, and we found no enrichment in any blood 
groups among patients infected with C. canimorsus com-
pared with the blood group distribution of the population 
of (data not shown).
The availability of clinical records associated with 
the isolates typed in this study gave us the opportunity to 
investigate the link between capsular serovar and disease 
severity, patient immune status, lifestyle, or type of contact 
with dogs. When comparing the most prevalent capsular 
types (A, B, and C) found in these 73 clinical isolates, we 
found no significant correlation between disease severity 
and capsular type. In the previous C. canimorsus capsular 
typing study, the authors suggested that strains belonging 
to capsular types of lower prevalence, like D and E, might 
preferentially infect immunocompromised patients (7); we 
could not draw such a conclusion here. In addition, alcohol 
abuse or smoking status could not be linked to infection 
by a specific capsular type. Alcohol abuse, smoking status, 
and immune suppression all were not significantly associ-
ated with disease severity or the 30-day mortality rate (data 
not shown), although the relatively low sample size and 
missing data preclude us from drawing conclusions regard-
ing this matter.
The capsular serovars less frequently isolated in hu-
man infections, such as E, I, and J, were mainly found in 
patients who had been bitten, which could suggest that 
these serovars are less virulent than serovars A–D, perhaps 
requiring a deeper inoculation to provoke an infection. Un-
fortunately, the information on dog exposure was missing 
for the patient infected with the serovar K strain.
Two patients included in this study were reportedly 
bitten on the same day by the same dog. The isolates from 
these 2 patients (H44 and H46) were both typed as capsu-
lar serovar C, suggesting that the same strain infected both 
patients. The 2 patients had a severe form of the infection, 
requiring treatment in an intensive care unit. This observa-
tion of 2 patients being infected by the same dog has not 
been reported previously and gives an indication of the epi-
demiology of disease.
The observation of so few cases of C. canimorsus in-
fection is indeed striking, considering that up to 74% of 
dogs carry C. canimorsus bacteria (14). We hypothesize 
that only a few C. canimorsus strains are virulent in hu-
mans, and few dogs carry these dangerous strains. In-
deed, the 3 most prevalent serovars in human infection 
(A–C), represent only 7.6% of the C. canimorsus iso-
lates from dogs (7), suggesting that a minority of dogs 
represent a risk for humans. This disease might be pre-
ventable in humans by identifying the dogs that carry 
these dangerous serotypes and specifically vaccinating 
them to eliminate the pathogen or drastically reduce 
pathogen shedding.
This work was financed by grant SOC 1510582 from the Belgian 
Walloon Region.
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From the Greek kapnos (“smoke”) for its dependence on carbon dioxide, which is a large component of smoke, Capnocytophaga canimorsus (Latin canis, “dog,” and morsus, “bite”) 
are gram-negative, facultatively anaerobic, rod-shaped bacteria that are part of the normal 
oral microbiota of dogs and cats. The genus was proposed to distinguish these bacteria from 
Cytophaga spp. (Greek kytos, “cell,” and phagein, “eat”), which also exhibit gliding motility. 
C. canimorsus was previously known as CDC group DF-2 (dysgonic fermenter type 2) and was 
first isolated from a 
man who had ex-
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dog bites and devel-
oped septicemia and 
meningitis. C. cani-
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Technical Appendix 
Technical Appendix Table 1. Description of method and sample used for 16S rDNA identification of 73 Capnocytophaga 
canimorsus isolates from study, Helsinki, Finland, 2000–2017 
Isolate ID Method used Sample used 
H1 UNamur Isolated colony 
H3 UNamur Isolated colony 
H4 UNamur Isolated colony 
H5 HUSLAB method 3 Directly from blood culture bottle 
H6 HUSLAB method 3 Directly from blood culture bottle 
H7 HUSLAB method 3 Directly from blood culture bottle 
H8 HUSLAB method 3 Directly from blood culture bottle 
H9 HUSLAB method 3 Isolated colony 
H10 HUSLAB method 3 Isolated colony 
H11 HUSLAB method 3 Directly from blood culture bottle 
H12 UNamur Isolated colony 
H13 HUSLAB method 3 Directly from blood culture bottle 
H14 HUSLAB method 3 Directly from blood culture bottle 
H15 HUSLAB method 3 Directly from blood culture bottle 
H16 HUSLAB method 3 Directly from blood culture bottle 
H17 HUSLAB method 3 Directly from blood culture bottle 
H18 HUSLAB method 3 Directly from blood culture bottle 
H19 HUSLAB method 3 Isolated colony 
H20 HUSLAB method 3 Directly from blood culture bottle 
H21 UNamur Isolated colony 
H22 HUSLAB method 3 Isolated colony 
H23 HUSLAB method 3 Isolated colony 
H24 UNamur Isolated colony 
H25 HUSLAB method 3 Directly from blood culture bottle 
H26 HUSLAB method 3 Isolated colony 
H27 HUSLAB method 3 Isolated colony 
H28 HUSLAB method 3 Isolated colony 
H29 HUSLAB method 3 Isolated colony 
H30 HUSLAB method 3 Isolated colony 
H31 HUSLAB method 3 Directly from blood culture bottle 
H33 HUSLAB method 3 Isolated colony 
H34 HUSLAB method 3 Isolated colony 
H35 HUSLAB method 3 Directly from blood culture bottle 
H36 HUSLAB method 3 Directly from blood culture bottle 
H37 HUSLAB method 3 Directly from blood culture bottle 
H38 HUSLAB method 3 Directly from blood culture bottle 
H39 HUSLAB method 3 Isolated colony 
H41 HUSLAB method 3 Directly from blood culture bottle 
H42 HUSLAB method 3 Directly from blood culture bottle 
H43 HUSLAB method 3 Directly from blood culture bottle 
H44 HUSLAB method 2 Isolated colony 
H45 HUSLAB method 2 Isolated colony 
H46 HUSLAB method 2 Isolated colony 
H47 HUSLAB method 2 Directly from blood culture bottle 
H48 HUSLAB method 2 Directly from blood culture bottle 
H49 HUSLAB method 1 Isolated colony 
H50 HUSLAB method 1 Isolated colony 
H51 HUSLAB method 1 Directly from blood culture bottle 
H52 HUSLAB method 1 Directly from blood culture bottle 
H53 HUSLAB method 1 Directly from blood culture bottle 
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Isolate ID Method used Sample used 
H55 HUSLAB method 1 Isolated colony 
H56 HUSLAB method 1 Directly from blood culture bottle 
H57 HUSLAB method 1 Directly from blood culture bottle 
H58 HUSLAB method 1 Directly from blood culture bottle 
H59 HUSLAB method 1 Directly from blood culture bottle 
H60 HUSLAB method 1 Isolated colony 
H62 HUSLAB method 1 Directly from blood culture bottle 
H63 HUSLAB method 1 Isolated colony 
H64 HUSLAB method 1 Isolated colony 
H65 HUSLAB method 1 Directly from blood culture bottle 
H67 HUSLAB method 1 Directly from blood culture bottle 
H68 HUSLAB method 1 Isolated colony 
H69 HUSLAB method 1 Directly from blood culture bottle 
H70 UNamur Isolated colony 
H71 UNamur Isolated colony 
H72 UNamur Isolated colony 
H73 UNamur Isolated colony 
H74 HUSLAB method 1 Directly from blood culture bottle 
H75 HUSLAB method 1 Isolated colony 
H76 UNamur Isolated colony 
H78 HUSLAB method 1 Directly from blood culture bottle 
H79 HUSLAB method 1 Isolated colony 
H80 HUSLAB method 1 Isolated colony 
Technical Appendix Table 2. Oligonucleotides used for typing Capnocytophaga canimorsus isolates, Helsinki, Finland, 2000–2017 
Name Sequence 5-3 Reference 
533R TTACCGCGGCTGCTGGCAC (11) 
FD1 mod AGAGTTTGATCYTGGYTYAG (11) 
CLSI-F TTGGAGAGTTTGATCMTGGCTC (12) 
Forward Bosshard AGAGTTTGATCMTGGCTCAG (12) 
Reverse Bosshard GTATTACCGCGGCTGCTG (12) 
27F AGAGTTTGATCCTGGCTCAG (13,14) 
1100R GGGTTGCGCTCGTTG (13,14) 
685R TCTACGCATTTCACCGCTAC (13,14) 
SeroA-fw CATACCATGGGAAAAAAAGTACCAATAGTTTTTATATTTAACC (10) 
SeroA-rev CCGCTCGAGTCATTTTTTTATCTTTTTTAATATATTCCAC (10) 
SeroB-fw CATACCATGGGAATTAACAAAATTCTAATAG (10) 
SeroB-rev CCGCTCGAGTTATTTTTTATTTTCATTAG (10) 
SeroC-fw GGCGTATATCGTTGCTATTTTGTATG (10) 
SeroC-rev CTATTAATATTTTCATTGTACACCACTTC (10) 
SeroD-fw GATTTAAAAAATATAGTATTTTAGGAATTATCG (10) 
SeroD-rev CTATACTTGTTCCCACTTTTTAGTTTC (10) 
SeroE-fw GGAGGAGGAAAAGTATTATTAGATTATC (10) 
SeroE-rev CTATTCATAATTCTTAAAGATACTTATCAATTC (10) 
SeroABC-fw CTTGGTTAGGTAAAGTTGCCTTAC (10) 
SeroABC-rev CAACATTTCTCCCATCTTATAATCCC (10) 
 
Technical Appendix Table 3. Description of 16S rDNA sequencing methods used for Capnocytophaga canimorsus isolates, 
Helsinki, Finland, 2000–2017 
Category 
Method name 
HUSLAB method 1 HUSLAB method 2 HUSLAB method 3 UNamur 
Forward primer 533R CLSI F CLSI F 27F 
Reverse primer FD1mod Reverse Bosshard Reverse Bosshard 1100R 
DNA polymerase AmpliTaq Gold 
(Applied Biosystems, 
Waltham, MA, USA) 
AmpliTaq Gold 
(Applied Biosystems. 








94°C for 10 min. 35 
cycles of 94°C for 15 
s, 55°C for 15 s, and 
72°C for 30 s 
95°C for 10 min. 30 
cycles of 94°C for 15 s, 
64°C for 15 s, and 
72°C for 30 s 
95°C for 2 min. 40 
cycles of 94°C for 15 
s, 64°C for 15 s, and 
72°C for 30 s 
5 cycles of 94°C for 30 s, 60°C for 2 
min, and 72°C for 3 min with a 
reduction of annealing temperature of 
1.5°C/cycle. 30 cycles of 94°C for 30s, 
52°C for 90 s, and 72°C for 3 min. 
Final elongation at 72°C for 10 min. 
Sequencing 
primer(s) 
533R Forward Bosshard Forward Bosshard 27F, 685R, and 1100R 
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Technical Appendix Table 4. Capnocytophaga canimorsus strains used in study, Helsinki, Finland, 2000–2017* 
Isolate ID Collection History and geographic origin Reference 
Cc1 BCCM/LMG 11511; CCUG 17234; 
strain P810; strain SSI P810 
BCCM/LMG <CCUG Sweden <W.Frederiksen <J.Ursing. Malmö. 
Sweden 
(1) 
Cc2 CCUG 70775 G. Wauters and M. Delmee. Cliniques Universitaires St Luc. Brussels. 
Belgium 
(2) 
Cc3 – G. Wauters and M. Delmee <Sint-Jan Hospital. Brugges. Belgium (3) 
Cc4 CCUG 70776 J. Schrenzel. Hopitaux Universitaires de Genève. Switzerland (4) 
Cc5 BCCM/LMG 28512. CCUG 70777 G. Wauters and M. Delmee <Clinic of Libramont. Libramont. Belgium (5) 
Cc6 CCUG 70778 KU Leuven. Leuven. Belgium (6) 
Cc7 – G. Wauters and M. Delmee. <KU Leuven. Leuven. Belgium (5) 
Cc8 – M. Delmee <Liège. Belgium (6) 
Cc9 BCCM/LMG 11510. CCUG 12569. 
CDC A3626 
BCCM/LMG. CCUG <R. Weaver. CDC. Atlanta. Georgia <Virginia. 
USA 
(7) 
Cc10 BCCM/LMG 11541. CCUG 24741. 
ATCC 35978. CDC C8936 
BCCM/LMG. MCCM. ATCC <R. Weaver. CDC. Atlanta. Georgia 
<California Health Department. California. USA 
(7) 
Cc11 BCCM/LMG 11551. CCUG 70779. 
MCCM 01373 
BCCM/LMG <MCCM <A. von Graevenitz. Unersität Zurich. 
Switzerland 
(7) 
Cc12 ATCC 35979. CDC 7120. CCUG 
53895 
ATCC <R.Weaver. CDC Atlanta Georgia <California Health Dept. 
<San Antonio Community Hospital. California. USA 
(8) 
Cc13 – F.S. Stals. Laurentius Ziekenhuis. Roermond. The Netherlands (9) 
Cc14 – R. Jarsumbeck. Medizinisches labor Ostsachsen. Dresden. Germany (6) 
Cc15 – K. Mühlemann. University Hospital Bern. Switzerland (6) 
Cc16 – G. Glupczynski. Centre Hospitalier Universitaire Mont Godinne <D. 
Olivier. Hopital Univ. Erasme. Brussels. Belgium 
(6) 
Cc17 – G. Glupczynski. Centre Hospitalier Universitaire Mont Godinne <D. 
Olivier. Hopital Univ. Erasme. Brussels. Belgium 
(6) 
Cc18 – G. Glupczynski. Centre Hospitalier Universitaire Mont Godinne <D. 
Olivier. Hopital Univ. Erasme. Brussels. Belgium 
(6) 
Cc19 – A. Magnette. Centre Hospitalier Universitaire Mont-Godinne <M 
Delmée <Clinique Saint Pierre. Ottignies. Belgium 
(6) 
Cc20 CCUG 55909 CCUG <E. Ek. Blood Department. PHLS. Göteborg. Sweden <UK 
National External Quality assessment. Colindale. London. UK 
(10) 
Cc21 CCUG 60839 CCUG <E. Ek. Blood Department. PHLS. Göteborg. Sweden (10) 
Cc22 CCUG 20318 CCUG <W. Frederiksen. Statens Seruminstitut. Copenhagen. 
Denmark 
(10) 
Cc23 CCUG 48899 CCUG <V. Roux and D. Raoult. Marseille. France (10) 
Cc24 CCUG 67384 CCUG <PHLS. Uddevalla <Trollhätten. Sweden (10) 
Cc25 CCUG 66222 CCUG <I. Adlerberth. Blood Department. PHLS. Sahlgrenska 




– Switzerland (6) 
CcD113-
CcD131† 
– Belgium (6) 
*All human isolates listed were from human septicemia cases except Cc4, which was isolated from a prosthetic aortitis case. ATCC, American Type 
Culture Collection; BCCM/LMG, Belgian Co-ordinated Collections of Micro-organisms, Laboratory of Microbiology, UGent; CCUG, Culture Collection 
University of Gothenburg; CDC, Centers for Disease Control and Prevention; MCCM, Medical Culture Collection Marburg; PHLS, Public Health 
Laboratory Services. 
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Mean SD Mean SD 
H12 100 0  6.2 0.6 
H24 10 2.2  100 0 
Cc5 9.4 2.1  6.1 0.4 
Cc6 9.6 2.3  6.4 0.5 
Cc9 10 2.6  6.4 0.6 
Cc12 9.7 2.3  7.5 1.0 
Cc4 10 2.9  7.4 1.4 
CcD3 6.9 0.7  5.5 0.4 
CcD5 7.2 1.3  5.9 0.3 
CcD6 7.6 1.8  6.4 0.8 
CcD10 7.1 1.2  7.2 0.4 
CcD13 6.4 1.2  5.7 0.5 
CcD16 6.9 1.5  6.2 0.4 
CcD18 8.4 2.1  6.9 0.7 
CcD20 9.6 2.3  6.9 0.8 
CcD25 6.6 1.1  6.0 0.4 
CcD33 7.2 1.7  7.1 1.4 
CcD34 8.7 2.0  6.4 1.9 
CcD35 43.5 4.0  5.8 0.3 
CcD37 6.2 1.3  5.6 0.2 
CcD39 6.7 1.5  5.7 0.3 
CcD40 7.4 1.8  7.0 1.3 
CcD43 7.4 1.3  5.9 0.3 
CcD44 6.3 1.2  5.4 0.2 
CcD47 7.0 1.9  5.8 0.3 
CcD51 7.6 2.0  6.4 1.0 
CcD52 8.3 1.5  7.0 1.9 
CcD53 7.6 1.9  6.3 0.4 
CcD57 7.3 1.9  7.2 3.0 
CcD58 9.9 4.1  6.8 0.8 
CcD63 7.2 1.1  5.8 0.2 
CcD68 8.0 2.8  5.8 0.4 
CcD69 8.6 3.1  5.6 0.4 
CcD71 8.8 2.0  5.7 0.4 
CcD73 7.1 1.4  6.9 1.3 
CcD76 6.8 1.3  5.4 0.2 
CcD77 7.6 1.6  6.7 0.5 
CcD80 7.3 1.4  6.2 0.6 
CcD81 7.6 0.6  8.2 2.3 
CcD84 7.6 1.0  7.1 0.5 
CcD89 8.5 1.3  8.0 0.7 
CcD96 7.6 1.0  12.4 8.3 
CcD101 9.3 1.8  12.2 8.7 
CcD104 7.6 0.8  10.8 7.3 
CcD105 8.7 1.5  8.4 2.9 
CcD106 9.5 1.8  11.2 2.9 
CcD113 7.5 1.1  11.2 7.5 
CcD115 7.5 1.5  11.8 8.2 
CcD116 8.0 1.6  10.1 5.8 
CcD117 8.1 1.8  12.8 8.6 
CcD118 7.2 1.1  11.6 7.3 
CcD119 7.6 1.5  11.5 7.4 
CcD120 7.4 1.6  12.4 9.6 
CcD122 8.8 1.6  11.5 8.8 
CcD124 7.2 1.2  12.2 9.4 
CcD126 7.3 1.3  11.3 8.2 
CcD129 8.1 1.6  9.4 3.8 
CcD130 8.4 1.6  14.7 10.2 
CcD131 7.1 1.8  12.2 9.2 
*Capsular serotyping was determined by ELISA on entire heat-killed 
bacteria. The following sera were used: anti-H12 adsorbed with human 
isolates Cc1 to Cc25 (J antiserum) and anti-H24 adsorbed with human 
isolates Cc1 to Cc25 (K antiserum). Isolates Cc5, Cc6, Cc9, Cc12, and 
Cc4, which were serovars A–E, respectively, were used as negative 
controls. The readout of the ELISA was absorbance but results are 
expressed here as percentage of reactivity calculated with respect to the 
absorbance value obtained for the capsular type strain. Values are the 
mean and SD of at least 3 independent experiments. 
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Technical Appendix Figure 1. Capsular typing of Capnocytophaga canimorsus isolates from patients, 
Helsinki, Finland, 2000–2017, by PCR. PCR detection of capsular serovars A–E with oligonucleotides 
given in Technical Appendix Table 2. The capsular type of each serovar described in reference (10) were 
used as positive controls: Cc5, Cc6 (6), Cc9 (7), Cc12 (American Type Culture Collection 35979) (8), and 
Cc4 (4) for A, B, C, D, and E serovars, respectively. For PCR ABC, Cc5 was used as a positive control. A 
strain of another capsular type and no DNA were used as negative controls. Three strains were identified 
by 16S rDNA sequencing to be a member of other dog-hosted Capnocytophaga species and were 
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Technical Appendix Figure 2. Capsular serotyping of Capnocytophaga canimorsus isolates from 
patients, Helsinki, Finland, 2000–2017, by Western blot. Western blot analysis of proteinase-K treated 
lysates of C. canimorsus isolates by using A–K antisera. Cc5, Cc6, Cc9, Cc12, Cc4, CcD37 (6), CcD63 
(6), CcD101 (6), and CcD129 (6) were used as positive controls for capsular serovars A–I, respectively. 
Numbers correspond to molecular mass (kDa). Three strains were identified by 16S rDNA sequencing to 
be members of other dog-hosted Capnocytophaga species and were removed from our study and from 
this figure by cutting out the according lanes. 
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